Association Between Dry Eye and Polycystic Ovary Syndrome: Subclinical Inflammation May Be Part of the Process.
Journal
Eye & contact lens
ISSN: 1542-233X
Titre abrégé: Eye Contact Lens
Pays: United States
ID NLM: 101160941
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
accepted:
21
04
2020
pubmed:
5
6
2020
medline:
19
8
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
To evaluate the changes in tear function in patients with polycystic ovary syndrome (PCOS) and establish whether there is a correlation between hormonal levels, novel hematologic biomarkers, and dry eye parameters. Forty-seven patients with PCOS and 43 age-matched patients with unexplained infertility were included in the control group. Follicle-stimulating hormone, luteinizing hormone, estradiol, thyroid-stimulating hormone, prolactin, dehydroepiandrosterone sulfate (DHEA-S), 17-OH progesterone, fasting and postprandial glucose, fasting insulin, and cholesterol metabolites were evaluated in both groups. In addition, the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio were obtained from a complete blood count. The Ocular Surface Disease Index (OSDI) questionnaire was administered, and all patients underwent tear break-up time (BUT) and Schirmer I tests. Bivariate correlations were investigated using Spearman correlation coefficient analysis. The mean age of the PCOS group and the control group was 27.66±3.96 years and 29.28±6.83 years, respectively. Schirmer I test scores and BUT values were significantly lower and OSDI results were significantly higher in the PCOS group (P=0.003, P<0.001, and P=0.004). An inverse correlation was found between DHEA-S and BUT values in the PCOS group (r=-0.296, P=0.043). Similarly, a negative correlation was also present between NLR and BUT values in the PCOS group (r=-0.322, P=0.027). Dry eye can be well established by sensitive tests in patients with PCOS. The severity of dry eye may be correlated with the level of inflammation and hyperandrogenism.
Identifiants
pubmed: 32496281
pii: 00140068-202101000-00006
doi: 10.1097/ICL.0000000000000716
doi:
Substances chimiques
Luteinizing Hormone
9002-67-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-31Informations de copyright
Copyright © 2020 Contact Lens Association of Ophthalmologists.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2009;25:544–551.
Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: Involvement of genetic and environmental factors. Int J Androl 2006;29:278–285.
Wenner MM, Taylor HS, Stachenfeld NS. Androgens influence microvascular dilation in PCOS through ET-A and ET-B receptors. Am J Physiol Endocrinol Metab 2013;305:e818–e825.
Sprung VS, Cuthbertson DJ, Pugh CJ, et al. Nitric oxide-mediated cutaneous microvascular function is impaired in polycystic ovary syndrome but can be improved by exercise training. J Physiol 2013;591:1475–1487.
Burchall GF, Piva TJ, Linden MD, et al. Comprehensive assessment of the hemostatic system in polycystic ovarian syndrome. Semin Thromb Hemost 2016;42:55–62.
Bonini S, Mantelli F, Moretti C, et al. Itchy-dry eye associated with polycystic ovary syndrome. Am J Ophthalmol 2007;143:763–771.
Yavas GF, Ozturk F, Kusbeci, et al. Meibomian gland alterations in polycystic ovary syndrome. Curr Eye Res 2008;33:133–138.
Coksuer H, Ozcura F, Oghan F, et al. Effects of hyperandrogenism on tear function and tear drainage in patients with polycystic ovary syndrome. J Reprod Med 2011;56:65–70.
Baudouin C. The pathology of dry eye. Surv Ophthalmol 2001;45:211–220.
McCulley JP, Shine WE. The lipid layer of tears: Dependent on meibomian gland function. Exp Eye Res 2004;78:361–365.
Sullivan DA, Sullivan BD, Ullman MD, et al. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci 2000;41:3732–3742.
Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus workshop group. Fertil Steril 2012;97:28–38.
Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol 2000;118:615–621.
Gonen T, Celik C, Oznur M, et al. Tear osmolarity and ocular surface changes in patient with polycystic ovary syndrome. Curr Eye Res 2013;38:621–625.
Yuksel B, Ozturk I, Seven A, et al. Tear function alterations in patients with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 2015;19:3556–3562.
Baser G, Yildiz N, Calan M. Evaluation of meibomian gland dysfunction in polycystic ovary syndrome and obesity. Curr Eye Res 2016;42:661–665.
Schirra F, Suzuki T, Dickinson DP, et al. Identificantion of steroidogenic enzyme mRNAs in the human lacrimal gland, meibomian gland, cornea, and conjunctiva. Cornea 2006;25:438–442.
Vassiliadi DA, Barber TM, Hughes BA, et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:3558–3566.
Sullivan DA, Hann LE. Hormonal influence on the secretory immune system of the eye: Endocrine impact on the lacrimal gland accumulation and secretion of IgA and IgG. J Steroid Biochem 1989;34:253–262.
Mitchell S, Abel P, Madaan S, et al. Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia 2002;4:9–18.
Sullivan DA, Krenzer KL, Sullivan BD, et al. Does androgen insufficiency cause lacrimal gland infl ammation and aqueous tear deficiency? Invest Ophthalmol Vis Sci 1999;40:1261–1265.
Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640–650.
Toda I, Sullivan BD, Wickham LA, et al. Gender and androgen-related influence on the expression of protooncogene and apoptotic factors mRNAs in lacrimal glands of autoimmune and non-autoimmune mice. J Steroid Biochem Mol Biol 1999;71:49–61.
Apter D, Bützow T, Laughlin GA, et al. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab 1995;80:2966–2973.
Bhathena RK. Insulin resistance and the long-term consequences of polycystic ovary syndrome. J Obstet Gynaecol 2011;31:105–110.
Erkan M, Albayrak M, Karatas A, et al. Are insulin resistance and serum resistin levels increased in women with idiopathic hirsutism? Eur Rev Med Pharmacol Sci 2014;18:1889–1895.
Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic syndrome. Transl Res 2016;167:257–280.
Çakıroğlu Y, Vural F, Vural B. The inflammatory markers in polycystic ovary syndrome: Association with obesity and IVF outcomes. J Endocrinol Invest 2016;39:899–907.
Duleba AJ, Dokras A. Is PCOS an inflammatory process? Fertil Steril 2012;97:7–12.
Herlihy AC, Kelly RE, Hogan JL, et al. Polycystic ovary syndrome and the peripheral blood white cell count. J Obstet Gynaecol 2011;31:242–244.
Kan E, Emektar E, Corbacioglu K, et al. Evaluation of relationship between inflammatory markers and hyperemesis gravidarum in patients admitted to emergency department. Am J Emerg Med 2020;38:292–295.
Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: A retrospective study. Cornea 2012;31:472–478.